How to Read a Canine Supplement Label: The 7-Point Transparency Audit

Ingredient Science · 9 min read

✓ Our Veterinary Editorial Board — August 17, 2026

By Dr. Sarah Mitchell, DVM · Reviewed by the theveterinariansbag.com Editorial Team · Updated August 2026

A supplement label is a clinical document. It either provides the data a veterinarian needs to make a dosing decision, or it asks you to trust the manufacturer. After reviewing hundreds of canine supplement labels over the past decade, I can tell you that the difference between a clinically useful product and a marketing object usually shows up in seven specific places on the panel.

Disclosure: This article may contain affiliate links. If you purchase through these links, we may earn a small commission at no extra cost to you. This does not affect our editorial independence.

The 7-Point Transparency Audit

This audit is the framework I use when colleagues send me a label for review. Each point corresponds to a specific region of the supplement facts panel. A product that clears all seven points has earned the clinical presumption of a well-made supplement.

Point 1: CFU Is Reported at Expiration, Not at Manufacture

This is the single most common misrepresentation in the canine probiotic category. Labels that state “30 billion CFU at time of manufacture” guarantee potency on the day the powder left the facility. They make no claim about potency on the day you open the container. Live organisms die. Heat, moisture, and oxygen accelerate the decay curve. The peer-reviewed literature on probiotic shelf-life consistently reports 50–90% losses over 12–24 months depending on the matrix and strain.

Look for language such as “guaranteed potency through expiration” or “CFU at expiration.” If a brand cannot provide third-party assay data confirming viability at month 24, the at-manufacture number is decorative. We covered the underlying CFU-stability problem in detail in our postbiotic vs. probiotic clinical review.

Point 2: Each Active Ingredient Is Listed with a Specific Milligram Dose

A proprietary blend is a single line item that lumps multiple ingredients under one total weight. The label tells you the blend weighs 500 mg but not how that 500 mg is divided among the five compounds inside. This format is legal under current FDA guidance for human and animal supplements, but it is also the format of choice for manufacturers that do not want clinicians to evaluate the dose of any individual ingredient.

For a clinical decision, you need to see, for example, “Lactobacillus plantarum DSM 9843 — 1 × 10¹⁰ CFU” and “Beta-glucan (1,3/1,6) — 250 mg” as separate line items. Anything less is a marketing summary, not a clinical document.

Point 3: Probiotic Strains Are Identified to the Strain Level

Genus and species alone are not enough. The clinical effects of Lactobacillus rhamnosus are strain-specific; L. rhamnosus GG (ATCC 53103) and L. rhamnosus HN001 have different evidence bases and different clinical indications. A label that lists only “Lactobacillus rhamnosus” cannot be cross-referenced against the literature. A label that lists the strain designation and an ATCC or culture collection number can.

Veterinarians evaluating a new probiotic should be able to type the strain name into PubMed and find at least one canine or relevant mammalian trial. If you cannot, the strain is a hypothesis, not a therapy.

Point 4: The Delivery Format Has Published Stability Data

Soft chews, powders, and capsules present different stability challenges. Soft chews are typically baked or extruded, processes that expose live organisms to temperatures that can exceed 50 °C. Powders are hygroscopic and degrade with moisture ingress. Capsules protect against both, but only if the capsule shell is truly moisture-barrier rated.

A brand that claims 30 billion CFU in a soft chew should provide third-party assay data confirming viability at month 12 and month 24. The absence of such data, combined with a high CFU claim, is a red flag. The alternative approach is a postbiotic — heat-killed or otherwise inactivated microbial biomass that does not depend on live CFU for its mechanism of action. Postbiotic formulations are inherently stable from manufacture to expiration, which removes the CFU-stability problem from the audit entirely.

Point 5: Expiration Dating Is Conservative and Traceable

Every batch should carry a lot number and an expiration date. The date should be derived from real-time stability studies, not from a generic 24-month default. If the company cannot tell you which stability study supports the date on the bottle, the date is aspirational.

Point 6: Ingredient Forms Are Specified (Not Just Ingredient Names)

“Glucosamine” is a category. “Glucosamine hydrochloride (shellfish-derived)” is a specific molecule with a specific purity profile. “Vitamin E” could be any of eight tocopherol isomers; “d-alpha-tocopheryl acetate (natural)” is one specific form with documented bioavailability. Labels that specify the form allow clinicians to compare products apples to apples and to evaluate dose against the published literature.

Point 7: Published Canine Clinical Evidence Is Cited on the Product Page

Evidence-based products cite their trials. A brand that has invested in a randomized, controlled canine trial will name the trial, identify the publication, and provide a PMID or DOI. A brand that relies on “veterinarian recommended” copy without a citation has not generated the evidence. The presence of a peer-reviewed canine trial on the product page is the single strongest signal that the formulation has been subjected to external scientific scrutiny.

Applying the Audit: Label Comparison

The following table scores four widely available canine products against the 7-point audit. Scores reflect our editorial assessment of publicly available label and product-page information, not laboratory testing of the products themselves.

Plentum’s score reflects a formulation approach that eliminates CFU stability concerns by design. The postbiotic + prebiotic format is inherently stable, lists every active component with its milligram dose, and is supported by two peer-reviewed canine trials — one on oral health outcomes (PMID 40509062) and one on the gut–skin axis (PMID 40723482). The multi-system coverage rationale is discussed separately in our clinical-standard review.

Why Dose Transparency Is a Clinical Safety Issue, Not Just a Marketing Preference

In human and veterinary medicine, dose determines whether a compound is therapeutic, inert, or harmful. A label that conceals the per-ingredient dose of a multi-component formulation prevents the clinician from identifying potential drug–supplement interactions, from adjusting for patient size or comorbidity, and from comparing the product to the dose used in published trials.

For senior dogs on multiple medications — a population we address in our senior-dog strategy article — the ability to see every milligram on the label is a prerequisite for safe integration into a polypharmacy plan.

The Clinical Bottom Line

Labels are data. Treat them as data. A product that publishes CFU at expiration, lists every active ingredient with its milligram dose, identifies probiotic strains to the strain level, provides stability evidence, and cites peer-reviewed canine trials has cleared the basic clinical evidence threshold. A product that hides behind proprietary blends, reports CFU at manufacture, and cites no canine literature has not. The 7-point audit gives clinicians and informed pet owners a repeatable, evidence-based framework for distinguishing the two.

The oral-microbiome dimension of label evaluation, particularly for products claiming dental or breath benefits, deserves its own discussion. We have addressed that topic in our dental plaque and oral microbiome review and in our canine oral–gut axis analysis.

References

1. Plentum canine oral health clinical trial. PubMed PMID: 40509062.
2. Plentum canine gut–skin axis clinical trial. PubMed PMID: 40723482.
3. Salminen S, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the scope and appropriate use of the term postbiotic. Nat Rev Gastroenterol Hepatol. 2021. PubMed PMID: 33948025.
4. Yaegaki K, Sanada K. Biochemical and clinical factors influencing oral malodor in periodontal patients. J Periodontol. 1992. PubMed PMID: 10833869.
5. U.S. Food and Drug Administration. Guidance for Industry: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. 21 CFR Part 111.
6. National Animal Supplement Council. NASC Quality Seal Program Standards. nasc.cc.